Pharmaceuticals, Biotechnology and Life Sciences
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sanofi’s…
The startup company Novel Concepts Medical has announced major breakthrough in its research of COVID-19. Its novel plant-based treatment has…
Phase 1/2 clinical study in patients with advanced solid tumor expected to start in 2Q2022 SEONGNAM-SI, South Korea–(BUSINESS WIRE)–Qurient Co.…
The European Commission (EC) approved Sanofi’s Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.…
AstraZeneca’s Tagrisso has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor…
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the…
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use…
The U.S. Food and Drug Administration approved a new indication for Astellas Pharma’s Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Bayer has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive advanced or recurrent solid tumors.